IKBKB (O14920) variants and mutations
IKBKB (also known as O14920) is a human protein-coding gene encoding an inhibitor of nuclear factor kappa-B kinase subunit beta protein. It phosphorylates inhibitory I-kappaB proteins after immune-receptor activation, allowing NF-kappaB transcription factors to enter the nucleus and drive inflammatory and survival genes. Biallelic loss-of-function variants can cause severe combined immunodeficiency. This analysis covers 909 IKBKB variants and mutations. Of these, 71% have computational variant effect predictions. Disease context includes severe combined immunodeficiency due to IKK2 deficiency, immunodeficiency 15a, and severe combined immunodeficiency. Example IKBKB variants include M1?, S2N, and W3*.
Variant analysis overview
- Gene: IKBKB
- Protein: O14920
- UniProt accession: O14920
- Organism: Homo sapiens
- Variants analyzed: 909
- Variant scope: all variants
- Completed: 2026-08-22
Variant and mutation evidence
- Variant composition: 730 unspecified-consequence records; 96 missense variants; 61 synonymous variants; 14 frameshift variants; 6 stop-gained variants; 2 stop lost; 1 in-frame deletions; 1 splice-region variants; 4 substitution
- Prediction scores: 643 variants have prediction scores (71% of the analyzed set).
Clinical, disease, and population context
- Disease context: 25 disease associations are represented. Top associations: severe combined immunodeficiency due to IKK2 deficiency, immunodeficiency 15a, severe combined immunodeficiency, COVID-19, combined immunodeficiency, plasma cell myeloma, lung carcinoma, systemic lupus erythematosus, skin basal cell carcinoma, colorectal adenocarcinoma, endometrial endometrioid adenocarcinoma, carcinoma of liver and intrahepatic biliary tract.
Protein structure and variant hotspots
- Protein features: 1 domains; 2 binding sites; 18 post-translational modification sites.
- Structural context: 407 variants have structural context.
- PTM context: 13 variants overlap post-translational modification sites.
Data sources
Evidence in this analysis draws on EBI Proteins Variation, UniProt, gnomAD v4, EuropePMC, 3D Hotspot Analysis, Interaction Network Analysis, Protein Data Bank, AlphaFold DB, gnomAD constraint, Open Targets, ClinGen, MaveDB, LitVar.
Notable IKBKB variants
Examples include M1?, S2N, W3*, W3L, S4*, S4T, S4L, S4S. Listed records include available protein-change notation, database identifiers, clinical classifications, computational predictions, population evidence, experimental measurements, and disease context.
- M1?, NCI-TCGA Cosmic COSV1006, cosmic curated COSV10064, Variant assessed as somatic; high impact.
- S2N (p.Ser2Asn), rs1298511635, NCI-TCGA Cosmic COSV1006, cosmic curated COSV10064, TOPMed rs1298511635, REVEL 0.13, CADD 21.90, Variant assessed as somatic; moderate impact.
- W3* (p.Trp3Ter), Ensembl rs1807904663
- W3L (p.Trp3Leu), rs1807904663, ClinGen CA371088099, ClinVar RCV002906067, Uncertain significance, Inborn genetic diseases
- S4* (p.Ser4Ter), rs2487009371, ClinGen CA371088118, ClinVar RCV003416953, Likely pathogenic
- S4T (p.Ser4Thr), gnomAD 8-42272110-T-A, REVEL 0.10, MetaLR 0.20
- S4L (p.Ser4Leu), gnomAD 8-42272111-C-T, REVEL 0.15, MetaLR 0.26
- S4S (p.Ser4Ser), rs781711025, gnomAD 8-42272112-A-G, CADD 14.30
- P5L (p.Pro5Leu), rs201805807, ClinGen CA175977200, ClinVar RCV002047082, ClinVar RCV004631754, REVEL 0.49, CADD 27.00, Uncertain significance, not provided; Inborn genetic diseases; Severe combined immunodeficiency due to I
- P5T (p.Pro5Thr), rs2487009451, ClinGen CA371088140, ClinVar RCV003584023, REVEL 0.42, CADD 25.00, Uncertain significance, Severe combined immunodeficiency due to IKK2 deficiency
- S6F (p.Ser6Phe), Ensembl rs1585485440, REVEL 0.31, CADD 22.50
- L7M (p.Leu7Met), gnomAD 8-42272119-C-A, REVEL 0.16, MetaLR 0.22
- L7R (p.Leu7Arg), gnomAD 8-42272120-T-G, REVEL 0.33, MetaLR 0.21
- L7L (p.Leu7Leu), rs1198885814, gnomAD 8-42272121-G-A, CADD 12.60
- T8R (p.Thr8Arg), gnomAD 8-42272123-C-G, REVEL 0.06, MetaLR 0.16
- T9M (p.Thr9Met), cosmic curated COSV10064, ExAC rs748672861, TOPMed rs748672861, gnomAD rs748672861, REVEL 0.19, CADD 21.60
- T9A (p.Thr9Ala), gnomAD 8-42272125-A-G, REVEL 0.08, MetaLR 0.23
- T9T (p.Thr9Thr), rs756486665, gnomAD 8-42272127-G-A, CADD 8.63
- Q10P (p.Gln10Pro), gnomAD rs1159923087, REVEL 0.40, CADD 23.80
- T11I (p.Thr11Ile), rs1388981077, ClinGen CA371088276, ClinVar RCV001967241, gnomAD rs1388981077, REVEL 0.13, CADD 22.40, Uncertain significance, Severe combined immunodeficiency due to IKK2 deficiency
- T11T (p.Thr11Thr), gnomAD 8-42272133-A-C, CADD 8.41
- C12W (p.Cys12Trp), rs1807909696, gnomAD 8-42272132-CAT-C, CADD 27.70
- G13E (p.Gly13Glu), rs2487009900, ClinGen CA371088307, ClinVar RCV003095723, REVEL 0.44, CADD 27.40, Uncertain significance, Severe combined immunodeficiency due to IKK2 deficiency
- A14T (p.Ala14Thr), cosmic curated COSV10968, gnomAD rs1458065391, REVEL 0.02, CADD 15.60
- A14V (p.Ala14Val), Ensembl rs976797635
- W15* (p.Trp15Ter), NCI-TCGA Cosmic COSV1006, cosmic curated COSV10064, Variant assessed as somatic; high impact.
- E16K (p.Glu16Lys), NCI-TCGA Cosmic COSV6059, cosmic curated COSV60596, Variant assessed as somatic; moderate impact.
- M17V (p.Met17Val), gnomAD 8-42272149-A-G, REVEL 0.18, MetaLR 0.05
- K18K (p.Lys18Lys), rs1325687220, gnomAD 8-42272154-A-G, CADD 14.10
- E19D (p.Glu19Asp), ExAC rs778171429, gnomAD rs778171429
- R20C (p.Arg20Cys), rs1443757982, NCI-TCGA Cosmic COSV6059, cosmic curated COSV60599, gnomAD rs1443757982, REVEL 0.27, CADD 26.80, Variant assessed as somatic; moderate impact.
- R20H (p.Arg20His), ExAC rs749580126, TOPMed rs749580126, gnomAD rs749580126, REVEL 0.20, CADD 24.80
- R20L (p.Arg20Leu), ExAC rs749580126, TOPMed rs749580126, gnomAD rs749580126, REVEL 0.23, CADD 23.50, Uncertain significance, Severe combined immunodeficiency due to IKK2 deficiency
- R20S (p.Arg20Ser), gnomAD rs1443757982, REVEL 0.21, CADD 23.20
- R20R (p.Arg20Arg), rs771305431, gnomAD 8-42272160-C-T, CADD 6.71
- L21F (p.Leu21Phe), gnomAD 8-42272161-C-T, REVEL 0.49, MetaLR 0.48
- G22R (p.Gly22Arg), gnomAD rs1302668330
- T23T (p.Thr23Thr), rs1425144570, gnomAD 8-42272169-A-G, CADD 6.15
- G24G (p.Gly24Gly), rs774657314, gnomAD 8-42272172-G-C, CADD 14.00
- G25E (p.Gly25Glu), Ensembl rs2129978615
- G25R (p.Gly25Arg), gnomAD 8-42272173-G-A, REVEL 0.46, MetaLR 0.30
- G25A (p.Gly25Ala), gnomAD 8-42272174-G-C, REVEL 0.19, MetaLR 0.13
- F26I (p.Phe26Ile), rs762196216, gnomAD 8-42272169-A-AG, CADD 32.00
- F26L (p.Phe26Leu), gnomAD 8-42272269-T-C, CADD 0.72, SIFT 0.00
- N28I (p.Asn28Ile), NCI-TCGA Cosmic COSV1006, cosmic curated COSV10064, Variant assessed as somatic; moderate impact.
- N28N (p.Asn28Asn), rs1443315080, gnomAD 8-42272184-T-C, CADD 12.00
- V29I (p.Val29Ile), TOPMed rs1262686100, gnomAD rs1262686100, REVEL 0.65, CADD 26.50
- V29V (p.Val29Val), rs1330122110, gnomAD 8-42272187-C-A, CADD 14.00
- I30M (p.Ile30Met), rs1807917822, ClinGen CA371089029, NCI-TCGA Cosmic COSV6059, cosmic curated COSV60595, Uncertain significance, Severe combined immunodeficiency due to IKK2 deficiency
- I30V (p.Ile30Val), TOPMed rs1255966361, gnomAD rs1255966361, REVEL 0.04, CADD 20.70
- I30L (p.Ile30Leu), gnomAD 8-42272188-A-C, REVEL 0.25, MetaLR 0.05
- R31* (p.Arg31Ter), NCI-TCGA Cosmic COSV6059, cosmic curated COSV60596, Variant assessed as somatic; high impact.
- R31G (p.Arg31Gly), gnomAD 8-42272191-C-G, REVEL 0.34, MetaLR 0.15
- R31Q (p.Arg31Gln), gnomAD 8-42272192-G-A, REVEL 0.14, MetaLR 0.08
- R31R (p.Arg31Arg), rs200034788, gnomAD 8-42272193-A-G, CADD 8.26
- W32C (p.Trp32Cys), rs1807918890, gnomAD 8-42272194-TG-T, CADD 32.00
- H33R (p.His33Arg), gnomAD 8-42272198-A-G, REVEL 0.22, MetaLR 0.17
- H33H (p.His33His), rs745948519, gnomAD 8-42272199-C-T, CADD 12.80
- N34K (p.Asn34Lys), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- N34S (p.Asn34Ser), NCI-TCGA Cosmic COSV1006, cosmic curated COSV10064, Variant assessed as somatic; moderate impact.
- N34H (p.Asn34His), gnomAD 8-42272200-A-C, REVEL 0.17, MetaLR 0.08
- Q35E (p.Gln35Glu), NCI-TCGA Cosmic COSV6059, cosmic curated COSV60596, Variant assessed as somatic; moderate impact.
- Q35K (p.Gln35Lys), gnomAD 8-42272203-C-A, REVEL 0.10, MetaLR 0.06
- Q35H (p.Gln35His), gnomAD 8-42272205-G-C, REVEL 0.27, MetaLR 0.35
- E36G (p.Glu36Gly), ExAC rs750775522, TOPMed rs750775522, gnomAD rs750775522, REVEL 0.10, CADD 23.10, Uncertain significance, Severe combined immunodeficiency due to IKK2 deficiency
- E36A (p.Glu36Ala), gnomAD 8-42288635-A-C, REVEL 0.12, MetaLR 0.13
- T37T (p.Thr37Thr), rs144600166, gnomAD 8-42288639-A-G, CADD 8.56
- G38D (p.Gly38Asp), ExAC rs747115965, gnomAD rs747115965, REVEL 0.17, CADD 22.70
- G38R (p.Gly38Arg), ExAC rs780080409, gnomAD rs780080409, REVEL 0.45, CADD 25.10
- G38E (p.Gly38Glu), rs776492942, gnomAD 8-42272228-G-A, CADD 12.80, SIFT 0.00
- G38G (p.Gly38Gly), rs761778161, gnomAD 8-42272229-G-A, CADD 13.80
- G38S (p.Gly38Ser), gnomAD 8-42272233-G-A, CADD 4.33, SIFT 0.00
- G38W (p.Gly38Trp), rs200856271, gnomAD 8-42272236-G-T, CADD 0.09, SIFT 0.00
- G38A (p.Gly38Ala), rs201668433, gnomAD 8-42272237-G-C, CADD 1.49, SIFT 0.00
- E39G (p.Glu39Gly), ExAC rs768610309, gnomAD rs768610309, REVEL 0.52, CADD 25.50
- E39* (p.Glu39Ter), gnomAD 8-42288643-G-T, CADD 41.00
- E39D (p.Glu39Asp), gnomAD 8-42288645-G-T, REVEL 0.28, MetaLR 0.19
- E39E (p.Glu39Glu), gnomAD 8-42288645-G-A, CADD 8.96
- Q40E (p.Gln40Glu), Ensembl rs1811924643
- Q40* (p.Gln40Ter), gnomAD 8-42288646-C-T, CADD 40.00
- Q40Q (p.Gln40Gln), gnomAD 8-42288648-G-A, CADD 9.96
- I41F (p.Ile41Phe), gnomAD 8-42288649-A-T, REVEL 0.36, MetaLR 0.22
- I41M (p.Ile41Met), gnomAD 8-42288651-T-G, REVEL 0.28, MetaLR 0.18
- I41I (p.Ile41Ile), gnomAD 8-42288651-T-C, CADD 5.39
- A42V (p.Ala42Val), Ensembl rs1811925135, REVEL 0.84, CADD 26.90
- A42T (p.Ala42Thr), gnomAD 8-42272260-G-A, CADD 6.52, SIFT 0.00
- A42D (p.Ala42Asp), gnomAD 8-42272261-C-A, CADD 4.52, SIFT 0.00
- A42A (p.Ala42Ala), rs757629567, gnomAD 8-42272262-C-G, CADD 4.94
- A42S (p.Ala42Ser), gnomAD 8-42288652-G-T, REVEL 0.79, MetaLR 0.71
- I43V (p.Ile43Val), gnomAD 8-42288655-A-G, REVEL 0.08, MetaLR 0.08
- K44R (p.Lys44Arg), NCI-TCGA TCGA novel, Variant assessed as somatic; moderate impact.
- K44E (p.Lys44Glu), gnomAD 8-42288658-A-G, REVEL 0.97, MetaLR 0.81
- Q45L (p.Gln45Leu), gnomAD 8-42288662-A-T, REVEL 0.19, MetaLR 0.07
- Q45R (p.Gln45Arg), gnomAD 8-42288662-A-G, REVEL 0.13, MetaLR 0.07
- C46C (p.Cys46Cys), gnomAD 8-42272220-C-T, CADD 8.03
- R47Q (p.Arg47Gln), rs1363685414, TOPMed rs1363685414, REVEL 0.36, CADD 32.00, Variant assessed as somatic; moderate impact.
- R47W (p.Arg47Trp), rs777820763, ClinGen CA4731585, ClinVar RCV003133696, ExAC rs777820763, REVEL 0.66, CADD 32.00, Uncertain significance, not provided
- R47G (p.Arg47Gly), gnomAD 8-42272230-A-G, CADD 10.20, SIFT 0.00
- R47S (p.Arg47Ser), rs1490536162, gnomAD 8-42272230-A-AGC, CADD 7.49
- R47M (p.Arg47Met), gnomAD 8-42272231-G-T, CADD 6.21, SIFT 0.00
- R47K (p.Arg47Lys), rs765044169, gnomAD 8-42272231-G-A, CADD 6.72, SIFT 0.01
- R47R (p.Arg47Arg), gnomAD 8-42288669-G-T, CADD 9.30
- Q48L (p.Gln48Leu), gnomAD 8-42288671-A-T, REVEL 0.12, MetaLR 0.07
- E49G (p.Glu49Gly), ExAC rs749197733, gnomAD rs749197733, REVEL 0.53, CADD 32.00
- E49D (p.Glu49Asp), rs1807931885, gnomAD 8-42272241-G-T, CADD 1.65, SIFT 0.01
- E49E (p.Glu49Glu), rs1231379660, gnomAD 8-42288675-G-A, CADD 9.91
- L50F (p.Leu50Phe), ExAC rs770750173, TOPMed rs770750173, gnomAD rs770750173, REVEL 0.25, CADD 25.30
- L50V (p.Leu50Val), ExAC rs770750173, TOPMed rs770750173, gnomAD rs770750173
- L50L (p.Leu50Leu), gnomAD 8-42272215-C-T, CADD 13.90
- L50R (p.Leu50Arg), gnomAD 8-42272216-T-G, CADD 2.65, SIFT 0.00
- L50W (p.Leu50Trp), rs767985812, gnomAD 8-42272222-GC-G, CADD 9.32
- L50I (p.Leu50Ile), gnomAD 8-42272251-C-A, CADD 3.99, SIFT 0.00
- L50H (p.Leu50His), rs756678740, gnomAD 8-42272252-T-A, CADD 5.01, SIFT 0.00
- S51C (p.Ser51Cys), gnomAD 8-42272221-A-T, CADD 1.29, SIFT 0.00
- S51R (p.Ser51Arg), gnomAD 8-42272223-C-G, CADD 11.10, SIFT 0.00
- S51S (p.Ser51Ser), gnomAD 8-42272265-C-G, CADD 0.12
- S51P (p.Ser51Pro), gnomAD 8-42272311-T-C, CADD 5.94, SIFT 0.00
- S51L (p.Ser51Leu), gnomAD 8-42272312-C-T, CADD 1.69, SIFT 0.00
- S51* (p.Ser51Ter), gnomAD 8-42272312-C-A, CADD 1.28
- S51T (p.Ser51Thr), gnomAD 8-42272314-T-A, CADD 6.82, SIFT 0.00
- S51Y (p.Ser51Tyr), gnomAD 8-42272315-C-A, CADD 3.46, SIFT 0.00
- S51I (p.Ser51Ile), gnomAD 8-42272324-G-T, CADD 8.84, SIFT 0.00
- P52A (p.Pro52Ala), ExAC rs774165537, gnomAD rs774165537, REVEL 0.06, CADD 15.40
- P52L (p.Pro52Leu), rs200992566, gnomAD 8-42272213-C-T, CADD 7.92, SIFT 0.00
- P52P (p.Pro52Pro), gnomAD 8-42272244-A-T, CADD 1.21
- P52T (p.Pro52Thr), rs759102113, gnomAD 8-42272248-C-A, CADD 0.55, SIFT 0.00
- P52H (p.Pro52His), gnomAD 8-42272279-C-A, CADD 1.34, SIFT 0.00
- P52R (p.Pro52Arg), gnomAD 8-42288683-C-G, REVEL 0.11, MetaLR 0.16
- R53Q (p.Arg53Gln), cosmic curated COSV60599, ExAC rs201288942, TOPMed rs201288942, gnomAD rs201288942, REVEL 0.07, CADD 23.60
- R53W (p.Arg53Trp), cosmic curated COSV60596, TOPMed rs1214631042, gnomAD rs1214631042, REVEL 0.32, CADD 24.30, Uncertain significance, Severe combined immunodeficiency due to IKK2 deficiency
- R53G (p.Arg53Gly), gnomAD 8-42288680-GC-G, CADD 22.60
- R53R (p.Arg53Arg), gnomAD 8-42288685-C-A, CADD 9.71
- R53L (p.Arg53Leu), gnomAD 8-42288686-G-T, REVEL 0.29, MetaLR 0.19
- N54K (p.Asn54Lys), rs1485660870, ClinGen CA371092549, ClinVar RCV003744152, gnomAD rs1485660870, REVEL 0.11, CADD 19.60, Uncertain significance, Severe combined immunodeficiency due to IKK2 deficiency
- R55* (p.Arg55Ter), rs1190950389, ClinGen CA371092552, ClinVar RCV001903991, gnomAD rs1190950389, CADD 35.00, Pathogenic
- R55Q (p.Arg55Gln), cosmic curated COSV10441, TOPMed rs1000600256, REVEL 0.17, CADD 23.90, Uncertain significance, Severe combined immunodeficiency due to IKK2 deficiency
- R55R (p.Arg55Arg), rs1190950389, gnomAD 8-42288691-C-A, CADD 10.10
- E56D (p.Glu56Asp), TOPMed rs1186913596, gnomAD rs1186913596, REVEL 0.05, CADD 9.63
- E56Q (p.Glu56Gln), gnomAD rs1454239284, REVEL 0.18, CADD 22.70
- E56E (p.Glu56Glu), rs1186913596, gnomAD 8-42288696-G-A, CADD 6.18
- R57Q (p.Arg57Gln), cosmic curated COSV60598, ExAC rs774942847, TOPMed rs774942847, gnomAD rs774942847, REVEL 0.62, CADD 30.00
- R57W (p.Arg57Trp), TOPMed rs1270112519
- R57R (p.Arg57Arg), gnomAD 8-42288697-C-A, CADD 12.80
- R57L (p.Arg57Leu), gnomAD 8-42288698-G-T, REVEL 0.74, MetaLR 0.43
- R57P (p.Arg57Pro), gnomAD 8-42288698-G-C, REVEL 0.72, MetaLR 0.47
- W58C (p.Trp58Cys), gnomAD 8-42272304-G-T, CADD 2.01, SIFT 0.00
- W58S (p.Trp58Ser), gnomAD 8-42272304-G-GCTT, CADD 3.04
- W58* (p.Trp58Ter), gnomAD 8-42272309-G-A, CADD 6.53
- W58R (p.Trp58Arg), rs1165970201, gnomAD 8-42272317-T-A, CADD 9.53, SIFT 0.00
- W58L (p.Trp58Leu), gnomAD 8-42272318-G-T, CADD 5.83, SIFT 0.00
- L60L (p.Leu60Leu), rs1811936644, gnomAD 8-42288708-G-T, CADD 10.60
- E61* (p.Glu61Ter), gnomAD 8-42288709-G-T, CADD 42.00
- Q63H (p.Gln63His), TOPMed rs910056341, gnomAD rs910056341
- Q63R (p.Gln63Arg), gnomAD 8-42288716-A-G, REVEL 0.32, MetaLR 0.17
- Q63Q (p.Gln63Gln), rs910056341, gnomAD 8-42288717-G-A, CADD 11.70
- I64V (p.Ile64Val), gnomAD 8-42288718-A-G, REVEL 0.36, MetaLR 0.31
- R66R (p.Arg66Arg), rs1563286532, gnomAD 8-42272290-A-C, CADD 3.54
- R66K (p.Arg66Lys), rs769782452, gnomAD 8-42272291-G-A, CADD 2.63, SIFT 0.00
- R67S (p.Arg67Ser), cosmic curated COSV60599, Ensembl rs1812304259
- R67G (p.Arg67Gly), gnomAD 8-42288725-GA-G, CADD 24.20
- R67M (p.Arg67Met), gnomAD 8-42288728-G-T, REVEL 0.38, MetaLR 0.26
- L68=, rs1440778745, NCI-TCGA Cosmic COSV1006, Variant assessed as somatic; low impact.
- L68R (p.Leu68Arg), rs2487292120, ClinGen CA371092874, ClinVar RCV003743065, Uncertain significance, Severe combined immunodeficiency due to IKK2 deficiency
- L68F (p.Leu68Phe), gnomAD 8-42272299-C-T, CADD 1.07, SIFT 0.00
- L68P (p.Leu68Pro), gnomAD 8-42272300-T-C, CADD 6.17, SIFT 0.00
- L68L (p.Leu68Leu), rs1807953579, gnomAD 8-42272301-T-C, CADD 6.33
- T69I (p.Thr69Ile), rs779345275, gnomAD 8-42272267-C-T, CADD 3.32, SIFT 0.00
- H70Y (p.His70Tyr), gnomAD rs1277286371, REVEL 0.83, CADD 24.90
- H70D (p.His70Asp), gnomAD 8-42272296-C-G, CADD 8.12, SIFT 0.00
- H70Q (p.His70Gln), gnomAD 8-42272297-A-AG, CADD 6.24
- H70H (p.His70His), gnomAD 8-42272298-C-T, CADD 7.74
- P71L (p.Pro71Leu), rs2487292229, ClinGen CA371092921, ClinVar RCV003743321, Uncertain significance, Severe combined immunodeficiency due to IKK2 deficiency
- P71T (p.Pro71Thr), gnomAD 8-42272287-C-A, CADD 0.21, SIFT 0.00
- P71S (p.Pro71Ser), rs747010102, gnomAD 8-42272287-C-T, CADD 0.27, SIFT 0.00
- P71P (p.Pro71Pro), gnomAD 8-42272289-A-G, CADD 6.37
- N72S (p.Asn72Ser), rs771764280, ClinGen CA4731607, ClinVar RCV001321633, ExAC rs771764280, REVEL 0.47, CADD 26.10, Uncertain significance, Severe combined immunodeficiency due to IKK2 deficiency
- V73M (p.Val73Met), rs2487292327, ClinGen CA371092947, ClinVar RCV004402889, REVEL 0.56, CADD 29.90, Uncertain significance, Inborn genetic diseases
- V73V (p.Val73Val), gnomAD 8-42290174-G-A, CADD 10.50, SIFT 0.13
- V74M (p.Val74Met), ExAC rs775274100, gnomAD rs775274100, REVEL 0.60, CADD 29.90
- V74L (p.Val74Leu), gnomAD 8-42290175-G-T, REVEL 0.54, MetaLR 0.37
Public IKBKB analysis runs
- IKBKB analysis run — IKBKB (909 variants) — completed 2026-08-22